1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular disease and cancer are the two leading causes of death worldwide. Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular disease encompasses a range of conditions extending from myocardial infarction to congenital heart disease most of which are heritable. Sodium reduction can reduce long term risk of cardiovascular events. Statin therapy is an effective intervention in the secondary prevention of cardiovascular events in both sexes.

Cardiovascular Disease Related Products (428):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13948
    Angiotensin II human 4474-91-3
    Angiotensin II human is converted by Angiotensin I through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE). Angiotensin II is mediated by AT1 and AT2 receptors, which are seven transmembrane glycoproteins with 30% sequence similarity.
    Angiotensin II human
  • HY-15515
    SEA0400 223104-29-8
    SEA0400 is a novel and selective inhibitor of the Na+-Ca2+ exchanger (NCX), inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50s of from 5 to 33 nM.
    SEA0400
  • HY-17512A
    Losartan potassium 124750-99-8
    Losartan (potassium) is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
    Losartan potassium
  • HY-17502
    Simvastatin 79902-63-9
    Simvastatin is a competitive inhibitor of HMG-CoA reductase with Kd of 0.1-0.2 nM.
    Simvastatin
  • HY-13715B
    Norepinephrine bitartrate monohydrate 108341-18-0
    Norepinephrine bitartrate monohydrate is a β1-selective adrenergic receptor agonist with EC50 of 5.37 μM.
    Norepinephrine bitartrate monohydrate
  • HY-15778
    AVE 0991 304462-19-9
    AVE 0991 is a nonpeptide and orally active Ang-(1-7) agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21±35 nM.
    AVE 0991
  • HY-A0064
    Verapamil hydrochloride 152-11-4
    Verapamil hydrochloride is an L-type calcium channel antagonist.
    Verapamil hydrochloride
  • HY-12298
    GKT137831 1218942-37-0
    GKT137831 is a novel, specific dual NADPH oxidase (NOX1/4) inhibitor. GKT137831 has potency both on human Nox4 (Ki=140±40 nM) and human Nox1 (Ki=110±30 nM) and is found 15-fold less potent on Nox2 (Ki=1750±700 nM) and 3-fold less potent on Nox5 (Ki=410±100 nM).
    GKT137831
  • HY-12403
    Angiotensin 1-7 51833-78-4
    Angiotensin (1-7) inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC50 of 0.65 μM.
    Angiotensin 1-7
  • HY-14779
    Riociguat 625115-55-1
    Riociguat is an oral stimulator of soluble guanylate cyclase (sGC), and used in the treatment of ipulmonary hypertension.
    Riociguat
  • HY-17379
    Atorvastatin hemicalcium salt 134523-03-8
    Atorvastatin (hemicalcium salt) is a potent HMG-CoA reductase inhibitor with the IC50 value of 8 nM.
    Atorvastatin hemicalcium salt
  • HY-B0468
    Isoprenaline hydrochloride 51-30-9
    Isoprenaline (hydrochloride) is a non-selective beta-adrenergic receptor agonist, used for the treatment of bradycardia and heart block.
    Isoprenaline hydrochloride
  • HY-17459
    Clopidogrel hydrogen sulfate 120202-66-6
    S-(+)-Clopidogrel Hydrogen Sulfate is the S enantiomer of clopidogrel and a P2Y12 receptor inhibitor.
    Clopidogrel hydrogen sulfate
  • HY-15718A
    Istaroxime hydrochloride 374559-48-5
    Istaroxime hydrochloride is a potent inhibitor of Na+,K+-ATPase with IC50 of 0.11 μM.
    Istaroxime hydrochloride
  • HY-P0017
    Aprotinin 9087-70-1
    Aprotinin is a serine protease inhibitor isolated from bovine lung which inhibits trypsin and chymotrypsin with Ki values of 0.06 pM and 9 nM, respectively.
    Aprotinin
  • HY-17376
    Ezetimibe 163222-33-1
    Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator. Ezetimibe (Eze) is a potent cholesterol absorption inhibitor.
    Ezetimibe
  • HY-15556
    GSK269962A 850664-21-0
    GSK269962A is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively.
    GSK269962A
  • HY-14184
    Macitentan 441798-33-0
    Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan
  • HY-10627A
    GW3965 hydrochloride 405911-17-3
    GW3965 (hydrochloride) is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively.
    GW3965 hydrochloride
  • HY-13749
    Sitagliptin 486460-32-6
    Sitagliptin is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.
    Sitagliptin